ERBB2 and ductal breast carcinoma in situ: Amplification of HER2 in DCIS is more frequent than in invasive carcinoma35,36 and for some authors may represent a precursor of invasion37–39 In the NSABP B43 trial, transtuzumab was used as chemopreventive treatment for DCIS with HER2 amplification.39